glp 1 drugs for cardiovascular health The effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action From Fat Burn to Muscle

This concern was further highlighted by an analysis of the US FDA adverse events database

2 Low risk of hypoglycemia GLP-1 agonists also have a low risk of hypoglycemia

Society for Vascular Medicine

in fact, some clinical evidences suggest it may have a potential protective effect in reducing lung cancer risk

[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Gao Q., Jia Y., Yang G., Zhang X., Boddu P.C., Petersen B., Narsingam S., Zhu Y.J., Thimmapaya B., Kanwar Y.S., et al

GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis